FDA Authorizes Use of COVID-19 Antibody Therapy for Postexposure Prophylaxis
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
Diana Ernst, RPh
Editorial Director
Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.
